Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) released its quarterly earnings data on Thursday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.08), FiscalAI reports. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 189.06%. The company had revenue of $14.48 million for the quarter.

Here are the key takeaways from Senseonics Holdings, Inc. Common Stock’s conference call:

• Q2 revenue rose approximately 120% year over year to $14.5 million, led by U.S. revenue growth of more than 150% and continued adoption of Eversense 365. Management raised full-year 2026 revenue guidance to $62 million-$66 million, implying roughly 80% annual growth.
• Gross margin increased to 59%, the company’s strongest organic performance, supported by manufacturing improvements and a favorable reimbursement mix. Full-year gross margin guidance was raised to 58%-61% from 55%-58%.
• The Eon Care network expanded to more than 90 providers and performed a record number of insertions, accounting for approximately 40% of U.S. insertions in Q2. Management expects Eon to exceed 100 providers and represent more than half of U.S. insertions by year-end.
• The European commercial transition from Ascensia was completed, but delayed tender updates and inventory adjustments pushed some revenue into the third and fourth quarters. Management expects no full-year impact and continues to forecast Europe at approximately 20% of total 2026 revenue.
• Despite stronger revenue and margins, the net loss widened to $36.7 million from $14.5 million a year earlier as selling, general and administrative expenses rose sharply following the commercial transition and investments in Gemini and Freedom. The company expects 2026 operating expenses of $150 million-$160 million and cash utilization of $110 million-$120 million.

Senseonics Holdings, Inc. Common Stock Stock Performance

SENS stock traded up $1.87 during trading on Friday, hitting $7.02. 2,222,301 shares of the company’s stock traded hands, compared to its average volume of 466,007. Senseonics Holdings, Inc. Common Stock has a 52 week low of $4.79 and a 52 week high of $11.58. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.51 and a quick ratio of 3.19. The firm has a fifty day simple moving average of $5.85. The firm has a market capitalization of $293.44 million, a PE ratio of -3.15 and a beta of 1.01.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. HC Wainwright cut their target price on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Mizuho cut their price objective on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Stifel Nicolaus cut their price objective on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research report on Saturday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.20.

Insider Activity at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder bought 22,686 shares of Senseonics Holdings, Inc. Common Stock stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average cost of $5.56 per share, for a total transaction of $126,134.16. Following the acquisition, the director directly owned 144,635 shares in the company, valued at approximately $804,170.60. This represents a 18.60% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ausdal Financial Partners Inc. raised its position in Senseonics Holdings, Inc. Common Stock by 50.0% during the third quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after purchasing an additional 35,000 shares during the period. Townsend Asset Management Corp NC ADV bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at approximately $60,000. GSK plc purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter worth approximately $60,000. State of Wyoming purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth approximately $67,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the 1st quarter valued at approximately $68,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.